Insider Selling: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells 1,750 Shares of Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,750 shares of the company's stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $25.45, for a total transaction of $44,537.50. Following the transaction, the insider now owns 1,737 shares in the company, valued at approximately $44,206.65. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Scott Bizily also recently made the following trade(s):

• On Tuesday, April 16th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $25.74, for a total transaction of $45,045.00.
• On Monday, April 1st, Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $31.78, for a total transaction of $259,102.34.
• On Wednesday, March 27th, Scott Bizily sold 5,833 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $35.04, for a total transaction of $204,388.32.
• On Monday, March 18th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $31.27, for a total transaction of $54,722.50.
• On Tuesday, February 27th, Scott Bizily sold 1,909 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $57,270.00.

4D Molecular Therapeutics Stock Performance

FDMT traded up $0.66 during trading on Monday, reaching $26.00. 462,595 shares of the company traded hands, compared to its average volume of 932,040. 4D Molecular Therapeutics, Inc. has a 12-month low of $9.44 and a 12-month high of $36.25. The firm has a fifty day simple moving average of $27.82 and a 200 day simple moving average of $22.51. The company has a market cap of $1.34 billion, a P/E ratio of -10.66 and a beta of 2.94.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.07. 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative return on equity of 26.75%. The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $1.44 million. As a group, sell-side analysts expect that 4D Molecular Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. HC Wainwright reiterated a "buy" rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, May 13th. Jefferies Financial Group increased their price objective on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a "buy" rating in a research note on Monday, April 1st. Royal Bank of Canada increased their price objective on shares of 4D Molecular Therapeutics from $35.00 to $40.00 and gave the stock an "outperform" rating in a research note on Monday, April 15th. Barclays assumed coverage on shares of 4D Molecular Therapeutics in a report on Monday, April 15th. They issued an "overweight" rating for the company. Finally, The Goldman Sachs Group reissued a "buy" rating and issued a $81.00 target price on shares of 4D Molecular Therapeutics in a report on Wednesday, February 7th. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $44.22.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its position in shares of 4D Molecular Therapeutics by 16.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 135,711 shares of the company's stock valued at $1,728,000 after acquiring an additional 19,434 shares during the last quarter. Trexquant Investment LP bought a new position in shares of 4D Molecular Therapeutics during the 3rd quarter valued at approximately $566,000. Aigen Investment Management LP bought a new position in shares of 4D Molecular Therapeutics during the 3rd quarter valued at approximately $216,000. Wellington Management Group LLP boosted its position in shares of 4D Molecular Therapeutics by 2.2% during the 3rd quarter. Wellington Management Group LLP now owns 172,722 shares of the company's stock valued at $2,199,000 after acquiring an additional 3,638 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of 4D Molecular Therapeutics by 359.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,951 shares of the company's stock valued at $100,000 after acquiring an additional 3,873 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.